BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dörner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono S, Fantini D, Hoffman RW. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med 2020;7:e000424. [PMID: 33037080 DOI: 10.1136/lupus-2020-000424] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Crow MK. Advances in lupus therapeutics: Achieving sustained control of the type I interferon pathway. Current Opinion in Pharmacology 2022;67:102291. [DOI: 10.1016/j.coph.2022.102291] [Reference Citation Analysis]
2 Li Y, Ma C, Liao S, Qi S, Meng S, Cai W, Dai W, Cao R, Dong X, Krämer BK, Yun C, Hocher B, Hong X, Liu D, Tang D, He J, Yin L, Dai Y. Combined proteomics and single cell RNA-sequencing analysis to identify biomarkers of disease diagnosis and disease exacerbation for systemic lupus erythematosus. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.969509] [Reference Citation Analysis]
3 Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol 2022. [PMID: 36097207 DOI: 10.1038/s41584-022-00826-z] [Reference Citation Analysis]
4 Tucci G, Garufi C, Pacella I, Zagaglioni M, Pinzon Grimaldos A, Ceccarelli F, Conti F, Spinelli FR, Piconese S. Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes. Front Immunol 2022;13:932240. [DOI: 10.3389/fimmu.2022.932240] [Reference Citation Analysis]
5 Dörner T, Tanaka Y, Dow ER, Koch AE, Silk M, Ross Terres JA, Sims JT, Sun Z, de la Torre I, Petri M. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis 2022:annrheumdis-2022-222335. [PMID: 35609978 DOI: 10.1136/annrheumdis-2022-222335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC, Alatorre-alexander J, Altclas JD, Casas M, Cevolirecio V, Ellerin T, Giovanni Luz K, Goldman JD, Juliani Souza Lima MP, Khan A, Paulin P, Procopio Carvalho AC, Rojas Velasco G, Saraiva JFK, Shawa I, Simon Campos J, Tiffany B, Westheimer Cavalcante A. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. The Lancet Respiratory Medicine 2022;10:327-36. [DOI: 10.1016/s2213-2600(22)00006-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 40] [Article Influence: 27.0] [Reference Citation Analysis]
7 Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol 2022. [PMID: 35209781 DOI: 10.1080/1744666X.2022.2047022] [Reference Citation Analysis]
8 Santos GC, Martins LM, Bregadiolli BA, Moreno VF, Silva‐filho LC, Silva BHST. Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications. J Heterocyclic Chem 2021;58:2226-60. [DOI: 10.1002/jhet.4349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lan SH, Wang CK, Chang SP, Lu LC, Hung SH, Lin WT. Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34743661 DOI: 10.1080/14787210.2022.2004120] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
10 Connelly K, Morand EF. Filgotinib in cutaneous lupus: is a negative positive? Rheumatology (Oxford) 2021:keab856. [PMID: 34791095 DOI: 10.1093/rheumatology/keab856] [Reference Citation Analysis]
11 Joos L, Vetterli F, Jaeger T, Cozzio A, von Kempis J, Rubbert-Roth A. Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib. Clin Exp Dermatol 2021. [PMID: 34747511 DOI: 10.1111/ced.15005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Int J Mol Sci 2021;22:11286. [PMID: 34681945 DOI: 10.3390/ijms222011286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
13 Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC. Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial.. [DOI: 10.1101/2021.10.11.21263897] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
14 Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021:S2213-2600(21)00331-3. [PMID: 34480861 DOI: 10.1016/S2213-2600(21)00331-3] [Cited by in Crossref: 195] [Cited by in F6Publishing: 116] [Article Influence: 195.0] [Reference Citation Analysis]
15 Gallucci S, Meka S, Gamero AM. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine 2021;146:155633. [PMID: 34340046 DOI: 10.1016/j.cyto.2021.155633] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
16 Rajasimhan S, Pamuk O, Katz JD. Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk". Drugs Aging 2021;38:539-41. [PMID: 33871805 DOI: 10.1007/s40266-021-00856-4] [Reference Citation Analysis]
17 Chasset F, Dayer JM, Chizzolini C. Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment. Front Pharmacol 2021;12:633821. [PMID: 33986670 DOI: 10.3389/fphar.2021.633821] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
18 Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int J Mol Sci 2021;22:2449. [PMID: 33671049 DOI: 10.3390/ijms22052449] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
19 [DOI: 10.1101/2021.04.30.21255934] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Reference Citation Analysis]